131 related articles for article (PubMed ID: 19380173)
1. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.
Røe OD; Anderssen E; Sandeck H; Christensen T; Larsson E; Lundgren S
Lung Cancer; 2010 Jan; 67(1):57-68. PubMed ID: 19380173
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.
Røe OD; Anderssen E; Helge E; Pettersen CH; Olsen KS; Sandeck H; Haaverstad R; Lundgren S; Larsson E
PLoS One; 2009 Aug; 4(8):e6554. PubMed ID: 19662092
[TBL] [Abstract][Full Text] [Related]
3. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions.
Falleni M; Pellegrini C; Marchetti A; Roncalli M; Nosotti M; Palleschi A; Santambrogio L; Coggi G; Bosari S
Lung Cancer; 2005 May; 48(2):211-6. PubMed ID: 15829320
[TBL] [Abstract][Full Text] [Related]
4. Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma.
Røe OD; Szulkin A; Anderssen E; Flatberg A; Sandeck H; Amundsen T; Erlandsen SE; Dobra K; Sundstrøm SH
PLoS One; 2012; 7(8):e40521. PubMed ID: 22905093
[TBL] [Abstract][Full Text] [Related]
5. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma.
Melaiu O; Cristaudo A; Melissari E; Di Russo M; Bonotti A; Bruno R; Foddis R; Gemignani F; Pellegrini S; Landi S
Mutat Res; 2012; 750(2):132-140. PubMed ID: 22198210
[TBL] [Abstract][Full Text] [Related]
6. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
7. Malignant pleural mesothelioma: two cases in first degree relatives.
Wilkins A; Popat S; Hughes S; O'Brien M
Lung Cancer; 2007 Sep; 57(3):407-9. PubMed ID: 17400330
[TBL] [Abstract][Full Text] [Related]
8. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
Bronte G; Incorvaia L; Rizzo S; Passiglia F; Galvano A; Rizzo F; Rolfo C; Fanale D; Listì A; Natoli C; Bazan V; Russo A
Crit Rev Oncol Hematol; 2016 Nov; 107():20-32. PubMed ID: 27823648
[TBL] [Abstract][Full Text] [Related]
9. Advances in the systemic therapy of malignant pleural mesothelioma.
Fennell DA; Gaudino G; O'Byrne KJ; Mutti L; van Meerbeeck J
Nat Clin Pract Oncol; 2008 Mar; 5(3):136-47. PubMed ID: 18227828
[TBL] [Abstract][Full Text] [Related]
10. The role of epigenetics in malignant pleural mesothelioma.
Vandermeers F; Neelature Sriramareddy S; Costa C; Hubaux R; Cosse JP; Willems L
Lung Cancer; 2013 Sep; 81(3):311-318. PubMed ID: 23790315
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma.
Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Yeap BY; Sugarbaker DJ; Bueno R
J Pathol; 2007 Mar; 211(4):439-46. PubMed ID: 17253597
[TBL] [Abstract][Full Text] [Related]
12. Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets.
Crispi S; Cardillo I; Spugnini EP; Citro G; Menegozzo S; Baldi A
Curr Cancer Drug Targets; 2010 Feb; 10(1):19-26. PubMed ID: 20088796
[TBL] [Abstract][Full Text] [Related]
13. Translational therapies for malignant pleural mesothelioma.
Belli C; Anand S; Tassi G; Fennell D; Mutti L
Expert Rev Respir Med; 2010 Apr; 4(2):249-60. PubMed ID: 20406091
[TBL] [Abstract][Full Text] [Related]
14. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
[TBL] [Abstract][Full Text] [Related]
15. [Asbestos and malignant pleural mesothelioma: molecular, cellular and physiopathological aspects].
Mohr S; Keith G; Rihn B
Bull Cancer; 2005 Nov; 92(11):959-76. PubMed ID: 16316830
[TBL] [Abstract][Full Text] [Related]
16. Biology and management of malignant pleural mesothelioma.
Zucali PA; Giaccone G
Eur J Cancer; 2006 Nov; 42(16):2706-14. PubMed ID: 16989994
[TBL] [Abstract][Full Text] [Related]
17. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.
Fennell DA; Rudd RM
Lancet Oncol; 2004 Jun; 5(6):354-62. PubMed ID: 15172356
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma.
Gordon GJ; Mani M; Mukhopadhyay L; Dong L; Edenfield HR; Glickman JN; Yeap BY; Sugarbaker DJ; Bueno R
J Pathol; 2007 Mar; 211(4):447-54. PubMed ID: 17253596
[TBL] [Abstract][Full Text] [Related]
19. BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.
Hmeljak J; Erčulj N; Dolžan V; Kern I; Cör A
J Cancer Res Clin Oncol; 2011 Nov; 137(11):1641-51. PubMed ID: 21861135
[TBL] [Abstract][Full Text] [Related]
20. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.
Aoe K; Amatya VJ; Fujimoto N; Ohnuma K; Hosono O; Hiraki A; Fujii M; Yamada T; Dang NH; Takeshima Y; Inai K; Kishimoto T; Morimoto C
Clin Cancer Res; 2012 Mar; 18(5):1447-56. PubMed ID: 22261805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]